These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24107277)

  • 1. Questionnaire based assessment of patients' acceptability of leukocytapheresis for the treatment of inflammatory bowel disease.
    Nagase K; Fukuanga K; Yokoyama Y; Kamikozuru K; Miwa H; Nakamura S
    Ther Apher Dial; 2013 Oct; 17(5):490-7. PubMed ID: 24107277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and future perspectives of leukocytapheresis for inflammatory bowel disease.
    Fukunaga K; Matsumoto T
    J Gastroenterol Hepatol; 2012 Jun; 27(6):997-1003. PubMed ID: 22414250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A national survey on the patterns of treatment of inflammatory bowel disease in Canada.
    Hilsden RJ; Verhoef MJ; Best A; Pocobelli G
    BMC Gastroenterol; 2003 Jun; 3():10. PubMed ID: 12791168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocytapheresis for the treatment of IBD.
    Sigurbjörnsson FT; Bjarnason I
    Nat Clin Pract Gastroenterol Hepatol; 2008 Sep; 5(9):509-16. PubMed ID: 18665138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocytapheresis for treatment of IBD.
    Kohgo Y; Ashida T; Maemoto A; Ayabe T
    J Gastroenterol; 2003 Mar; 38 Suppl 15():51-4. PubMed ID: 12698872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: a small step for clinicians, a potentially large step for improving quality of care.
    Vasudevan A; Arachchi A; van Langenberg DR
    J Crohns Colitis; 2013 Oct; 7(9):e367-74. PubMed ID: 23528836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease.
    Sawada K
    Transfus Apher Sci; 2017 Oct; 56(5):689-697. PubMed ID: 28986009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study.
    Martín de Carpi J; Vilar P; Prieto G; García Novo MD; Ribes C; Varea V
    J Pediatr Gastroenterol Nutr; 2008 Apr; 46(4):386-91. PubMed ID: 18367949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of inflammatory bowel disease on Japanese patients' quality of life: results of a patient questionnaire survey.
    Ueno F; Nakayama Y; Hagiwara E; Kurimoto S; Hibi T
    J Gastroenterol; 2017 May; 52(5):555-567. PubMed ID: 27470433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health priorities in adolescents with inflammatory bowel disease: physicians' versus patients' perspectives.
    Cervesi C; Battistutta S; Martelossi S; Ronfani L; Ventura A
    J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):39-42. PubMed ID: 23403446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?
    Saniabadi AR; Hanai H; Suzuki Y; Ohmori T; Sawada K; Yoshimura N; Saito Y; Takeda Y; Umemura K; Kondo K; Ikeda Y; Fukunaga K; Nakashima M; Beretta A; Bjarnason I; Lofberg R
    J Clin Apher; 2005 Oct; 20(3):171-84. PubMed ID: 15892107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-related worries and concerns: a study on out-patients with inflammatory bowel disease.
    Moser G; Tillinger W; Sachs G; Genser D; Maier-Dobersberger T; Spiess K; Wyatt J; Vogelsang H; Lochs H; Gangl A
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):853-8. PubMed ID: 8574717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Yamada M; Kikuyama M; Maruyama Y; Iwaoka Y; Hirayama K; Nagata S; Takai K
    Am J Gastroenterol; 2008 May; 103(5):1210-6. PubMed ID: 18177452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
    Domènech E; Hinojosa J; Esteve-Comas M; Gomollón F; Herrera JM; Bastida G; Obrador A; Ruiz R; Saro C; Gassull MA;
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1347-52. PubMed ID: 15606397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease.
    Allen PB; Kamm MA; Peyrin-Biroulet L; Studd C; McDowell C; Allen BC; Connell WR; De Cruz PP; Bell SJ; Elliot RP; Brown S; Desmond PV; Lemann M; Colombel JF
    Aliment Pharmacol Ther; 2013 Feb; 37(4):438-44. PubMed ID: 23278192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementary medicine use by patients with inflammatory bowel disease.
    Hilsden RJ; Scott CM; Verhoef MJ
    Am J Gastroenterol; 1998 May; 93(5):697-701. PubMed ID: 9625111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease.
    Sawada K; Ohnishi K; Kosaka T; Fukui S; Yamamura M; Amano K; Satomi M; Shimoyama T
    J Gastroenterol; 1995 Nov; 30 Suppl 8():124-7. PubMed ID: 8563873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Life-threatening complications of Crohn's disease and ulcerative colitis: a systematic analysis of admissions to an ICU during 18 years].
    Huber W; Herrmann G; Schuster T; Phillip V; Saugel B; Schultheiss C; Hoellthaler J; Gaa J; Hartel M; Schmid RM; Reindl W
    Dtsch Med Wochenschr; 2010 Apr; 135(14):668-74. PubMed ID: 20358493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study.
    Sakata Y; Iwakiri R; Amemori S; Yamaguchi K; Fujise T; Otani H; Shimoda R; Tsunada S; Sakata H; Ikeda Y; Ando T; Nakafusa Y; Fujimoto K
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):629-33. PubMed ID: 18679064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway.
    Opheim R; Bernklev T; Fagermoen MS; Cvancarova M; Moum B
    Scand J Gastroenterol; 2012 Dec; 47(12):1436-47. PubMed ID: 23003678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.